DITROPAN by Johnson & Johnson is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency and 2 more indications. First approved in 1975.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
DITROPAN (oxybutynin chloride) is an oral anticholinergic agent approved in 1975 that exerts direct antispasmodic effects on bladder smooth muscle by inhibiting muscarinic acetylcholine action. It is indicated for overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults, and for pediatric patients aged 6+ with detrusor overactivity associated with neurological conditions.
As a mature product approaching loss of exclusivity, DITROPAN brand team faces transition planning and potential rightsizing; focus likely shifting toward generic defense or portfolio redeployment.
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on DITROPAN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DITROPAN offers limited growth opportunity and signals career risk due to LOE trajectory; roles focus on defensive commercial strategies, generic mitigation, and transition planning rather than innovation or expansion. This assignment is best suited for candidates seeking short-term stabilization or transition roles before portfolio redeployment.